Australia Markets closed

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.6100-0.1200 (-2.54%)
At close: 04:00PM EDT
4.4500 -0.16 (-3.47%)
After hours: 07:38PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.7300
Bid4.4500 x 1000
Ask4.7700 x 1200
Day's range4.5050 - 4.7800
52-week range2.5400 - 8.7300
Avg. volume968,075
Market cap392.789M
Beta (5Y monthly)0.44
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

    SAN CARLOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022. The Company’s most advanced antibodies are lirentelimab (AK002) and AK006. Recent Allakos Events Initiated a Phase 2b randomized, double-blind, placebo-cont

  • GlobeNewswire

    Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology

    – AK006 is an agonistic antibody that targets the mast cell inhibitory receptor Siglec-6 –– AK006 shows deep mast cell inhibition in pre-clinical studies and was engineered to have antibody-dependent cellular phagocytosis (ADCP) activity –– Allakos plans to initiate the first-in-human study of AK006 during 1H 2023 – SAN CARLOS, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory recept

  • GlobeNewswire

    Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

    – Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells –– AK007 potently blocks all known ligand interaction with Siglec-10, including the “don’t eat me” signal CD24 –– Monotherapy treatment with a Siglec-10 antagonist antibody polarized tumor-associated myeloid cells and reduced tumor burden in pre-clinical studies – SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology co